Uses of Usarinate

Usarinate is a drug circulated in Vietnam, registration number VD-23511-15, containing the main active ingredient Risedronate sodium. Usarinate is indicated in the treatment and prevention of osteoporosis. Usarinate is a prescription drug, so to ensure the effectiveness of using Usarinate, users need to follow the instructions of their doctor.

1.1. What is Usarinate? Usarinate is a drug belonging to the group of pain relievers, antipyretics, non-steroidal anti-inflammatory drugs (NSAIDs), drugs for the treatment of gout and bone and joint diseases. Usarinate medicine has the main ingredient Risedronate sodium (as Risedronate sodium hemipentahydrate) 35mg.
Usarinate drug is manufactured at Ampharco U.S.A Pharmaceutical Joint Stock Company and registered by Ampharco U.S.A Pharmaceutical Joint Stock Company. clamps, 6 blisters x 4 tablets.
1.2. What does Usarinate do? Indications for the use of Usarinate in the following cases:
Treatment and prevention of osteoporosis in post-menopausal women. Treatment and enhancement of bone mass in men with osteoporosis. Usarinate is contraindicated in the following cases:
Patients with esophageal malformations and delayed esophageal emptying such as: Narrow or non-dilated esophagus. Pregnant women and nursing mothers. The patient is unable to stand or sit upright for at least 30 minutes. Patients with severe renal impairment (creatinine clearance less than 30 ml per minute). Patients with hypersensitivity to all components of the drug. Patients with hypocalcemia (or low blood calcium levels)

2.1. How to take Usarinate Risedronate should be taken with a full glass of water (180 to 240ml) at least 30 minutes before eating and drinking or taking other medications for the first time of the day. Patients should take Risedronate whole tablets when in an upright position, and should avoid lying down for at least 30 minutes after taking the drug, should be supplemented with calcium and vitamin D if the daily diet does not meet the needs. enough. Calcium supplements and medicines containing calcium, aluminum, and magnesium can interfere with the absorption of risedronate sodium and should be taken at another time of day, like food. Usarinate should be taken on an empty stomach or at least 30 minutes before breakfast or at least 2 hours before other meals or possibly at least 30 minutes before going to bed. The tablet should be swallowed whole (do not need to be broken, sucked or chewed) with 1 glass of water (about 120 ml), and kept upright for at least 30 minutes after taking it to make it easier for the stomach to reach the stomach. . 2.2. Dosage of Usarinate Treatment of missed doses: If a dose of risedronate sodium is missed once a week, the patient should take 1 tablet in the morning after remembering and then continue taking it as usual each week. 1 capsule on a given day. Absolutely do not take 2 pills within a day.
Management of Overdose: After taking a serious overdose of Usarinate may lead to a decrease in serum calcium and phosphorus in some patients. In addition, some patients have signs and symptoms of hypocalcemia. If the patient takes an overdose of risedronate, it is recommended to take antacids containing magnesium, calcium, aluminum or should drink milk to bind risedronate sodium and reduce drug absorption. When a serious overdose occurs, the patient should be taken to the nearest medical facility, and the nearest hospital for immediate treatment for gastric lavage and removal of unabsorbed drug or intravenous calcium can be administered. to help restore ionized calcium, and relieve the signs and symptoms of hypocalcaemia.

There have been reports of esophageal complications such as esophageal ulceration, inflammation, esophageal erosion and sometimes accompanied by bleeding and rarely subsequent stricture or perforation of the esophagus in patients receiving treatment. by oral Usarinate. In some cases, these complications are severe and require hospitalization. Therefore, physicians should be on the lookout for any functional or physical symptoms that signal an esophageal reaction and patients should be instructed to stop taking Usarinate and consult a physician directly. if you find it difficult to swallow or swallow pain and experience pain behind the sternum. The risk of serious esophageal complications is greater in patients who lie down immediately after taking Usarinate. Patients should not swallow the tablet with a full glass of water (180 to 240 ml) or continue to take it when there are symptoms of esophageal irritation. Therefore, it is very important to provide complete instructions on drug use to patients to understand. Aseptic osteonecrosis of the jaw, which can be spontaneous, often following tooth extraction or a persistent local infection, has been reported in patients receiving bisphosphonates, including Usarinate. Discontinuation of bisphosphonate therapy in patients requiring invasive dental procedures may reduce the risk of aseptic osteonecrosis of the jaw. Rarely has this condition been reported with occasional severe loss of bone and joint mobility or muscle pain when treated with Usarinate. The duration of pain onset varied from 1 day to many years after the patient started treatment (time to onset varied on average about 3 months). If severe symptoms occur, Usarinate should be discontinued. The pain will usually improve after stopping the medication, but may recur as the patient continues to take the same drug or another Usarinate. Fractures of the femur that are atypical (under the trochanter or shaft), low impact or low trauma, rarely occur with long-term use of bisphosphonates (more than 3 years), mainly in patients taking bisphosphonates. bisphosphonates for the treatment of osteoporosis. Fractures usually occur with little or no trauma, and can be bilateral. There is some evidence (from circulating reports and observational studies) to suggest an association between oral use of Usarinate and an increased risk of esophageal cancer. However, because the data are conflicting, additional studies are needed to confirm these results. Oral bisphosphonates should be avoided in patients with Barrett's esophagus, a condition known to predispose to adenocarcinoma of the esophagus. When Usarinate is co-administered with calcium carbonate, a combination of cautions and cautions or contraindications related to risedronate and calcium carbonate should be considered. Asymptomatic reductions in serum calcium and phosphorus concentrations may occur. Hypocalcaemia and disturbances in bone and other mineral metabolism should be corrected before treatment is initiated. If the daily diet is not enough, the patient should be supplemented with calcium and vitamin D. Currently, there are no adequate data on the use of Usarinate in pregnant women. Animal studies have shown that genitourinary toxicity and potential risks to humans are unknown. Animal studies have shown that small amounts of risedronate sodium are excreted in human milk. Therefore, Usarinate should not be administered to pregnant or nursing women.

At therapeutic doses, Usarinate is well tolerated. However, during the use of Usarinate, patients may still experience side effects such as:
Common, ADR above 1/100:
Nervous system disorders such as pain or headache. Digestive disorders such as indigestion, nausea, abdominal pain, diarrhea or constipation. Musculoskeletal and connective tissue diseases: Pain in bones, muscles and joints. Uncommon, less than 1 in 1,000 ADR less than 1/100:
Digestive disorders: Gastritis, duodenitis, esophagitis and dysphagia. Eye disorders: Inflammation of the iris. Disorders of serum electrolytes such as hypophosphatemia, hypocalcemia. Rarely, 1/10,000 less than 1/1,000 ADR:
Immune system disorders: Hypersensitivity reactions such as angioedema, pruritic rash. Digestive disorders that cause narrowing of the esophagus or glossitis. Laboratory tests: Decrease white blood cells and liver enzyme disorders. If you experience these symptoms, the patient should stop using the drug Usarinate and notify the doctor for appropriate treatment.

When taken concomitantly with drugs containing polyvalent cations such as magnesium, calcium, iron and aluminum, may interfere with the absorption of Usarinate. These medications should be taken at a different time of day than when risedronate is taken. Usarinate can be used concurrently with estrogen supplements if carefully considered. Risedronate is not metabolized in the body, does not induce P450 enzymes and is poorly bound to proteins. With respect to acetylsalicylic acid or NSAIDs, among those who used acetylsalicylic acid or an NSAID regularly (for 3 or more days per week), the incidence of gastrointestinal adverse events in these patients treated with risedronate was similar. as in the control patients (when taking placebo).

Usarinate should be stored below 30 degrees Celsius, avoid direct sunlight and high temperatures doctor/pharmacist before use. Note, Usarinate is a prescription drug, patients need to use the drug as prescribed by the doctor, absolutely do not self-treat at home.